Community market perspectives and discussion for RLX Technology Inc. American Depositary Shares, each representing the right to receive one (1) Class A ordinary share (NYSE: RLX).
On our desk, the reaction to the Q2 print felt overdone. RLX posted a solid top-line beat with RMB 1,010.5 million in revenue, up 14.8% year-over-year, and gross margins expanded sharply to 35.4%. The 3% stock pullback looks like a knee-jerk reaction to management's guidance on second-half margin mix shifts rather than structural decay.
Looking at the balance sheet, RLX is sitting on RMB 13.9 billion in capital resources. That gives them massive optionality for accretive MandA and shareholder returns. However, the consolidation of the Western European distribution platform is going to structurally pull down percentage gross margins in H2. We are adjusting our valuation models to account for this geographic revenue mix shift.
As a hedge fund PM, I noticed a classic 'beat and down' scenario here. Revenue grew nicely, and non-GAAP income from operations rose 28.8% to RMB 149.6 million, marking their 11th consecutive profitable quarter. But missing Wall Street's profit expectations triggered a sell-off. International revenue now accounts for roughly 70% of total net revenues, cementing it as the primary growth engine.
Risk management note: Even though gross margins jumped from 27.5% to 35.4% this quarter thanks to supply chain optimization and product mix, the upcoming distribution consolidation in Western Europe will compress those percentage margins in the back half of the year. We are monitoring how trade inventory normalization following Q1 shipment pull-forwards impacts sequential growth.
From a regulatory and market positioning standpoint, mainland China sales are expected to stay flat year-over-year due to conservative approval timelines. Meanwhile, the U.S. strategy remains entirely sidelined with no large-scale capital commitment until regulatory clarity drastically improves. International expansion is doing all the heavy lifting.
The sentiment across retail and institutional boards is clearly split. Long-term bulls point to the 14.8% revenue increase and consistent profitability, while short-term traders are fixated on the second-half margin warning. At around US$1.94 post-earnings, the market is aggressively pricing in the distribution consolidation headwinds.
Explore plasma cleansing, somatic organ swaps, and BCI.